𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of concurrent carboplatin and radiotherapy in previously untreated patients with stage III and IV head and neck cancer

✍ Scribed by Dr. David Osoba; Dr. Albino D. Flores; Dr. John H. Hay; Dr. Frances Wong; Ms. Maureen Maher

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
599 KB
Volume
13
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

This study evaluated the toxicity resulting from combined therapy using carboplatin and radiotherapy in 22 patients with locally advanced (stage 111 and IV) head and neck cancer. Carboplatin was given after radiotherapy during the first 5 consecutive days of a 16-fraction course of radiotherapy delivered in a total of 22 days. To find the acceptable toxic dose of carboplatin, the patients were treated in groups of 3 patients each. The first group received 50 mg/m2 carboplatin and the dose was increased by 10 mg/m2 in each subsequent group. Unacceptable toxicity (severe mucositis, nausea and vomiting, and/or myelosuppression) was encountered at a carboplatin dose of 80 mg/ m2. A further 10 patients were then treated at a dose of 70 mg/ m2. At this dose toxicity was acceptable. Although the group of 22 patients is too small for response and survival data to be meaningful, 10 complete responses were seen and median survival is in excess of 67 weeks. HEAD & NECK 1991;31:217-223 T h e prognosis of patients with locally advanced head and neck cancer (T3, T4, or N2 or N3)

From the Divisions of Medical Oncology (Dr. Osoba), Radiation Oncology (Drs. Flores, Hay, and Wong). and Nursing (Ms. Maher), Vancouver Clinic,

πŸ“œ SIMILAR VOLUMES

A phase III randomized trial comparing c
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results
✍ David J. Adelstein; Jerrold P. Saxton; Pierre Lavertu; Laurie Tuason; Benjamin G πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

Background. A phase III randomized comparison of radiotherapy alone versus combination chemotherapy and concurrent continuous-course radiotherapy was performed at the Cleveland Clinic Foundation. Methods. Between March 1990 and June 1995, 100 patients with resectable stage III and IV squamous cell

Management of the neck in a randomized t
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer
✍ Pierre Lavertu; David J. Adelstein; Jerrold P. Saxton; Michelle Secic; John R. W πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

Background. Treating the neck after organpreservation treatment with radiotherapy or chemoradiotherapy can be problematic. Methods. To develop management guidelines, we reviewed the results of a 100-patient phase-3 trial that had compared outcome after radiotherapy alone with outcome after chemorad

Phase II trial of irinotecan, paclitaxel
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle